Navigation Links
GenVec Reports First Quarter 2011 Financial Results
Date:5/9/2011

uct development programs forward through collaborations," stated GenVec's Senior Vice President and Chief Financial Officer, Douglas J. Swirsky. "Based on our current operations we currently expect our cash burn this year will be between $6.0 million and $8.0 million. For 2011, we believe revenues from grants and collaborations will total between $20.0 million and $22.0 million."

Conference Call Information GenVec will hold a conference call at 10:00 a.m. EDT on Tuesday, May 10, 2011 to discuss the Company's first quarter results. To listen to the live conference call, please dial 877-558-0567 (U.S. or Canada) or 706-643-4980 (international) and use the following Conference ID: 63890121. An audio replay of the conference call will be available starting at 11:00 a.m. EDT on May 10, 2011 through May 17, 2011. To listen to the audio replay, dial 800-642-1687 or 706-645-9291 and use access code 63890121.

A live webcast of the conference call will be available on the Company's website and will be archived for 30 days. To access the webcast or the replay, go to www.genvec.com, click on "Investor Relations," and click on "Webcasts and Data."

About GenVecGenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss, balance disorders, and cancer; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus type 2 (HSV-2), dengue fever, influenza, mal
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
2. GenVec Expands Contract Supporting Malaria Vaccine Program
3. GenVec Reports Second Quarter 2009 Financial Results
4. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
5. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
6. GenVec Announces Third Quarter 2009 Results Conference Call
7. GenVec Reports Third Quarter 2009 Financial Results
8. Merriman Curhan Ford Acted as Placement Agent in GenVecs $28 Million Registered Offering
9. GenVec to Present at the 13th Annual BIO CEO & Investor Conference
10. GenVec To Host Fourth Quarter and Year-End 2010 Earnings Call and Webcast
11. GenVec, Inc. Announces Effectiveness of Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 BCC Research ( ... DIGITAL POLYMERASE CHAIN REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS , ... technology reached nearly $140 billion in 2013. This is ... a five-year compound annual growth rate (CAGR) of 28.6%. ... of interesting and exciting possibilities within the broader PCR ...
(Date:7/10/2014)... Burkina Faso (PRWEB) July 10, 2014 ... Faso, today have access to an additional family ... increase access to contraception at all levels of ... a lower-dose formulation of a widely used contraceptive—Pfizer’s ... system. , Burkina Faso is the first of ...
(Date:7/10/2014)... July 10, 2014 Unraveling life’s mysteries ... The Archer Family purchased a DNA test ... but ended up with a lifetime of memories, sharing, ... the family members’ DNA genuinely brought the family closer ... search deeper into genetic history and prior to taking ...
(Date:7/10/2014)... July 10, 2014  Franciscan St. Anthony ... capnography for respiratory monitoring outside the operating ... leaders in embracing state-of-the-art patient safety technology. ... are breathing and can alert medical caregivers ... the amount of carbon dioxide the patient ...
Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2
... database to explore, understand, manage, and share next-generation ... Inc., the leader in sequence data management, today ... Expression Workflow designed to enable researchers working with ... is the second such workflow to be delivered ...
... May 5 Sequella, Inc., a clinical-stage biopharmaceutical company ... start of its Phase 1B trial for SQ109 with ... a new diamine antibiotic intended to replace one or ... patient therapy, was granted U.S. FDA Fast Track designation ...
... influenza virus-like particle (VLP) vaccine progresses with study designed ... May 5 Novavax, Inc. (Nasdaq: NVAX ... second clinical trial of its virus-like particle (VLP) seasonal ... this Phase II randomized, placebo controlled clinical trial has ...
Cached Biology Technology:GenomeQuest, Inc. Announces Digital Gene Expression Solution Within Its Sequence Data Management Platform 2Sequella Commences Phase 1B Study for New Tuberculosis Drug SQ109 2Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate 2Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate 3Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate 4
(Date:7/11/2014)... 2014 Research and Markets has ... Market - Industry Analysis Size Share Growth Trends and ... http://photos.prnewswire.com/prnh/20130307/600769 The ... a need for high level security in both private ... such as username and passwords, tokens etc. are vulnerable ...
(Date:7/10/2014)... 2014  The American Academy of Forensic Sciences ... and Technology (NIST) and the Department of Justice ... forensic science expert members to the Forensic Science ... of the NIST,s Organization of Scientific Area Committees ... appointments made to the new FSSB that has ...
(Date:7/10/2014)... BLUE BELL, Pa. , July 2, 2014  Unisys ... The Netherlands , Unisys Nederland N.V., today announced that ... (DJI) to deliver, implement and manage a new Basic Provision ... . Unisys won the contract with a ... for identity management software. The term of the contract is ...
Breaking Biology News(10 mins):International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3
... its wood and cottony fibers, the kapok tree now ... for decades: the notion that African and South American ... million years ago. , Research by University of Michigan ... perhaps other rainforest--trees colonized Africa after the continents split ...
... modification to successfully manipulate the growth in height of trees, ... similar to normal trees – but after several years of ... few inches. , This is a “proof of concept” that ... It opens the door to a wide variety of new ...
... that will be published online in advance of its July ... colleagues (The Salk Institute and HHMI) demonstrate that endosomes can ... animals. , "These findings will influence our thinking of the ... why cells use them as signaling compartments," noted lead author ...
Cached Biology News:The kapok connection -- Study explains rainforest similarities 2Researchers demonstrate way to control tree height 2Researchers demonstrate way to control tree height 3
... tissue extracts (liver, kidney, spleen, and heart) and ... It was also tested with microsomal fractions prepared ... simple and reliable method for measuring NDPase activity ... the inorganic phosphate released from NDP by the ...
... CAST Equine EIA Principle: ... LTD4 and LTE4 are products ... 5-lipoxygenase and glutathione-S-transferase. In the ... "Slow Reacting Substances of Anaphylaxis ...
... stress is the condition in which a ... stimuli and the various antioxidants. Oxidative ... pathogenesis of several diseases, including artherosclerosis, chronic ... possesses several antioxidant systems that are very ...
... Compound(s) tested through ... enzyme assays spanning a ... assay panel includes many ... and several non-selective assays. ...
Biology Products: